Global Non-Insulin Therapies for Diabetes Market Size By Type (Alpha-glucosidase Inhibitors, Amylin Agonists), By Application (Monitoring, Diagnosis), By Region, And Segment Forecasts, 2023 to 2032

The Global Non-Insulin Therapies for Diabetes Market was valued at USD 24.3 billion in 2023 and is projected to reach USD 42.8 billion by 2031, expanding at a CAGR of 7.4% during the forecast period of 2023–2031. The market is witnessing robust growth due to rising diabetes prevalence worldwide, increasing patient preference for oral and non-invasive treatments, and the development of novel drug classes with fewer side effects. As healthcare systems aim for cost-effective, patient-friendly diabetes management solutions, non-insulin therapies are emerging as a cornerstone in treatment strategies, particularly for Type 2 Diabetes Mellitus (T2DM).

Drivers:

1. Rising Global Prevalence of Type 2 Diabetes:

With over 90% of diabetic patients affected by T2DM, the demand for convenient and effective treatment alternatives to insulin is escalating. Lifestyle changes, obesity, and aging populations are major contributors to this trend, significantly driving the need for non-insulin therapies.

2. Preference for Oral and Once-Daily Therapies:

Non-insulin treatments, especially oral drugs and GLP-1 receptor agonists in injectable forms, offer simplified regimens with minimal glycemic variability. Patients and providers prefer them for their ease of administration and reduced risk of hypoglycemia.

3. Advancements in Drug Development:

Breakthroughs in pharmacological research have led to new classes of non-insulin drugs like SGLT2 inhibitors and DPP-4 inhibitors, offering additional cardiovascular and renal benefits. This therapeutic evolution is attracting healthcare providers and fueling market adoption.

Restraints:

1. High Cost of New Therapies:

Despite their advantages, newer non-insulin treatments such as GLP-1 receptor agonists are relatively expensive, creating affordability challenges in low- and middle-income regions and limiting patient access.

2. Stringent Regulatory Requirements:

New drug development faces prolonged approval timelines due to strict clinical trial and regulatory frameworks, which can delay market entry and affect product pipeline expansion.

Opportunity:

1. Expanding Market in Emerging Economies:

Emerging economies in Asia-Pacific, Latin America, and parts of Africa are witnessing a rapid increase in diabetes prevalence. Improved healthcare infrastructure, growing awareness, and rising disposable incomes present significant market expansion opportunities.

2. Innovation in Combination Therapies:

Combination therapies integrating different non-insulin agents are gaining popularity due to their synergistic effects and better patient compliance. This trend is opening new revenue streams for pharmaceutical companies.

Market by System Type Insights:

Among the types of non-insulin therapies, SGLT2 Inhibitors held the largest market share in 2023. Their efficacy in lowering blood glucose, coupled with added cardiovascular and kidney protective effects, has positioned them as a first-line choice for many practitioners. However, the GLP-1 Receptor Agonists segment is expected to record the fastest growth during the forecast period, driven by newer formulations that allow once-weekly administration and weight loss benefits.

Market by End-Use Insights:

The Hospital Pharmacies segment dominated the market in 2023, contributing to more than 40% of total revenue. Hospitals are central to diabetes diagnosis and early treatment initiation. However, Retail Pharmacies are projected to see notable growth due to increasing availability of prescription therapies and growing patient trust in pharmacy-led chronic disease management services.

Market by Regional Insights:

North America led the global market in 2023, owing to its well-established healthcare infrastructure, high diabetes burden, and strong reimbursement environment for innovative therapies. The Asia-Pacific region is expected to witness the highest growth rate over the forecast period, attributed to rising healthcare investments, increasing awareness, and a surge in diabetes prevalence in countries like China and India.

Competitive Scenario:

Key players in the Global Non-Insulin Therapies for Diabetes Market include Novo Nordisk A/S, AstraZeneca plc, Merck & Co., Eli Lilly and Company, Johnson & Johnson, Boehringer Ingelheim, Sanofi, Bayer AG, Novartis AG, and Takeda Pharmaceutical Company Limited. These companies are focusing on expanding their product portfolios through strategic collaborations, clinical trials, and regional expansions. Notable developments include:

In 2024, Eli Lilly launched a novel once-weekly GLP-1 agonist with enhanced weight-loss effects.

In 2023, AstraZeneca expanded its SGLT2 inhibitor into additional indications including heart failure.

In 2022, Novo Nordisk received FDA approval for its oral GLP-1 therapy, revolutionizing convenience in administration.

Scope of Work – Global Non-Insulin Therapies for Diabetes Market

Report Metric Details

Market Size (2023) USD 24.3 billion

Projected Market Size (2031) USD 42.8 billion

CAGR (2023–2031) 7.4%

Market Segments By System Type (SGLT2 Inhibitors, GLP-1 RAs, DPP-4 Inhibitors),

By End-use (Hospitals, Retail Pharmacies, Online Pharmacies),

By Region

Growth Drivers Rising T2DM prevalence, patient preference for non-invasive therapies, cardiovascular benefits of new drug classes

Opportunities Growth in emerging markets, innovation in combination therapies

Key Market Developments:

2024: Novo Nordisk announced global expansion of its oral semaglutide to over 50 countries.

2023: Merck & Co. partnered with regional healthcare providers in Asia to distribute low-cost DPP-4 inhibitors.

2022: Sanofi initiated trials for a new dual-acting oral non-insulin drug targeting glycemic control and weight management.

FAQs:

1) What is the current market size of the Global Non-Insulin Therapies for Diabetes Market?

The market was valued at USD 24.3 billion in 2023.

2) What is the major growth driver of the Global Non-Insulin Therapies for Diabetes Market?

The key driver is the rising prevalence of Type 2 diabetes and the growing demand for non-invasive, patient-friendly treatment options.

3) Which is the largest region during the forecast period in the Global Non-Insulin Therapies for Diabetes Market?

North America accounted for the largest market share in 2023 and is expected to maintain its lead.

4) Which segment accounted for the largest market share in the Global Non-Insulin Therapies for Diabetes Market?

SGLT2 Inhibitors accounted for the largest market share in 2023.

5) Who are the key market players in the Global Non-Insulin Therapies for Diabetes Market?

Major players include Novo Nordisk, AstraZeneca, Merck, Eli Lilly, Boehringer Ingelheim, and Sanofi.